BioSpace News Archive

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its subsidiary Sapphire Biotech, Inc . (“Sapphire”) has started pre-clinical animal drug studies on its new compound, SPX-1009. “We look forward to the next step in the race to finding a cure for cancer,” said John W. Huemoeller II, Chief Executive Officer

Scientifically Formulated Nutraceutical Product Appears to Stimulate Natural Killer Cell Arm of Immune System Responsible for Suppression of Cancer and Viruses

Study Demonstrates Safety and Tolerability and its Potential Impact on Metabolism to Elicit Anti-Cancer Response in Brain Cancer

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern Time. The discussion will be available to all interested parties through a live webcast accessible via the Investors section of the LivaNova website at www.livanova.com . Listeners should log on approxi

Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun, Vuong Trieu. Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children. Clin Res Pediatr 2020; 3(1): 1-3 Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in

CVS Health Corporation announced that Eva Boratto, Executive Vice President and Chief Financial Officer, and Karen Lynch, Executive Vice President and President of Aetna, will be participating in a fireside chat with investors at the Goldman Sachs 41st Annual Healthcare Conference on June 10, 2020, at approximately 8:00 am ET.

Dr. Krishna’s main responsibilities will be to assist and advise Ehave on human trials for its cognitive and psychedelic opportunities.

Today, Change Healthcare (Nasdaq: CHNG) announced the acquisition of PDX, a leader in providing patient centric and innovative technologies for pharmacies and health systems.

Freitag will continue as member of board of directors and serve as special counsel in transitional role through October

The American Society of Plastic Surgeons – the world’s largest plastic surgery organization – leads the specialty’s medical professionals in navigating their practices’ recovery plans.